Vanzacaftor
- Generic Name
- Vanzacaftor
- Drug Type
- Small Molecule
- Chemical Formula
- C32H39N7O4S
- CAS Number
- 2374124-49-7
- Unique Ingredient Identifier
- COM1POP492
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 56
- Registration Number
- NCT05867147
- Locations
- πΊπΈ
Celerion - Tempe, Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 87
- Registration Number
- NCT03912233
- Locations
- π³π±
HagaZiekenhuis van den Haag, Den Haag, Netherlands
π³π±Erasmus Medical Center, Rotterdam, Netherlands
πΊπΈTulane Medical Center, New Orleans, Louisiana, United States
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: TEZ/IVADrug: Placebo (matched to VX-121 suspension)Drug: Placebo (matched to TEZ/IVA)Drug: Placebo (matched to IVA)Drug: IVADrug: Placebo (matched to VX-121 tablet)
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 115
- Registration Number
- NCT03768089
- Locations
- π³π±
HagaZiekenhuis van den Haag, Den Haag, Netherlands
π³π±Academic Medical Center, Amsterdam, Netherlands
π³π±UMC St. Radboud, Nijmegen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath